IL-2 activates lymphocytes into lymphokine-activated killer (LAK) cells, effective against multidrug-resistant cells and targeting lung metastasis sites (94, 95), underlining the potential of IL-2 and LAK/NK cell-based therapies in managing pediatric osteosarcoma lung metastases. Here, IL2 is linked to osteosarcoma.